These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 3882744)
61. Neutralization of heat-labile toxin of E. coli by antibodies to synthetic peptides derived from the B subunit of cholera toxin. Jacob CO; Pines M; Arnon R EMBO J; 1984 Dec; 3(12):2889-93. PubMed ID: 6098453 [TBL] [Abstract][Full Text] [Related]
62. Microtiter enzyme-linked immunosorbent assay for immunoglobulin G cholera antitoxin in humans: method and correlation with rabbit skin vascular permeability factor technique. Young CR; Levine MM; Craig JP; Robins-Browne R Infect Immun; 1980 Feb; 27(2):492-6. PubMed ID: 7189746 [TBL] [Abstract][Full Text] [Related]
63. Protection in rabbits induced by the Texas Star-SR attenuated A-B+ mutant candidate live oral cholera vaccine. Boesman-Finkelstein M; Finkelstein RA Infect Immun; 1982 Apr; 36(1):221-6. PubMed ID: 7076295 [TBL] [Abstract][Full Text] [Related]
64. Induction of polyclonal and monoclonal antibody responses to cholera toxin by the synthetic peptide approach. Ghose AC; Karush F Mol Immunol; 1988 Mar; 25(3):223-30. PubMed ID: 3374493 [TBL] [Abstract][Full Text] [Related]
65. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Connell TD Expert Rev Vaccines; 2007 Oct; 6(5):821-34. PubMed ID: 17931161 [TBL] [Abstract][Full Text] [Related]
66. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399 [TBL] [Abstract][Full Text] [Related]
67. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621 [TBL] [Abstract][Full Text] [Related]
68. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1. Karmali MA; Petric M; Winkler M; Bielaszewska M; Brunton J; van de Kar N; Morooka T; Nair GB; Richardson SE; Arbus GS J Clin Microbiol; 1994 Jun; 32(6):1457-63. PubMed ID: 8077389 [TBL] [Abstract][Full Text] [Related]
69. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. Clements ML; Levine MM; Young CR; Black RE; Lim YL; Robins-Browne RM; Craig JP J Infect Dis; 1982 Apr; 145(4):465-73. PubMed ID: 7069227 [TBL] [Abstract][Full Text] [Related]
70. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Nawar HF; Arce S; Russell MW; Connell TD Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982 [TBL] [Abstract][Full Text] [Related]
71. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. Clemens JD; Sack DA; Harris JR; Chakraborty J; Neogy PK; Stanton B; Huda N; Khan MU; Kay BA; Khan MR J Infect Dis; 1988 Aug; 158(2):372-7. PubMed ID: 3042876 [TBL] [Abstract][Full Text] [Related]
72. [Immunochemical characteristics of the subunits of cholera enterotoxin and of thermolabile Escherichia coli enterotoxins of various origins]. Voronov SE; Vertiev IuV; Shaginian IA; Ezepchuk IuV Biull Eksp Biol Med; 1987 Oct; 104(10):472-5. PubMed ID: 2445393 [TBL] [Abstract][Full Text] [Related]
73. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Negri DR; Pinto D; Vendetti S; Patrizio M; Sanchez M; Riccomi A; Ruggiero P; Del Giudice G; De Magistris MT Infect Immun; 2009 May; 77(5):1924-35. PubMed ID: 19223474 [TBL] [Abstract][Full Text] [Related]
74. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. de Haan L; Verweij W; Agsteribbe E; Wilschut J Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971 [TBL] [Abstract][Full Text] [Related]
75. Protection against human and porcine enterotoxigenic strains of Escherichia coli in rats immunized with a cross-linked toxoid vaccine. Klipstein FA; Engert RF; Clements JD; Houghten RA Infect Immun; 1983 Jun; 40(3):924-9. PubMed ID: 6343245 [TBL] [Abstract][Full Text] [Related]
76. Local intestinal immune response to Escherichia coli heat-labile (LT) enterotoxin: LT antitoxin levels in healthy, diseased and antigen-fed pigs. Pesti L; Lukács K Comp Immunol Microbiol Infect Dis; 1984; 7(3-4):149-55. PubMed ID: 6398185 [TBL] [Abstract][Full Text] [Related]
77. Immunochromatographic detection of the heat-labile enterotoxin of enterotoxigenic Escherichia coli with cross-detection of cholera toxin. Arimitsu H; Sasaki K; Tsuji T J Microbiol Methods; 2017 Jan; 132():148-152. PubMed ID: 27940044 [TBL] [Abstract][Full Text] [Related]